This loan aims to support progress in clinical development programs for OSE Immunotherapeutics’ leading products in therapeutic areas with high medical need.
Nantes, December 16, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Ticker: OSE) announces the drawing of 10 million euros for the second tranche of the loan granted by the European Investment Bank (EIB) on February 12, 2021.
After the drawdown of the first tranche in July 2021, the Company had an option to access an additional €10 million, subject to the achievement of specific milestones. These steps having been completed, the Company wished to consolidate its financial structure until the 3rd quarter of 2023 by drawing down the second tranche of this mechanism, in order to finance its pre-clinical and clinical programs.